We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
Read MoreHide Full Article
Key Takeaways
Inogen benefits from rising POC adoption, with ~59% of new LTOT patients choosing portable devices.
INGN expands beyond POCs, boosting TAM to $3B with Simeox, Voxi 5 and upcoming CPAP masks.
Inogen's international revenues rose 15% in Q4 2025, while U.S. sales fell 5.1% amid channel shifts.
Inogen, Inc. (INGN - Free Report) is well-poised for growth in the coming quarters, backed by high prospects in the portable oxygen concentrator (POC) space. The optimism, led by a diversified and expanding product portfolio, strong momentum in international markets and a growing total addressable market, seems justified. However, U.S. revenue pressure from channel shifts and macroeconomic conditions remains a key risk.
This Zacks Rank #3 (Hold) company’s shares have gained 3.6% in the year-to-date period against the industry’s 12.7% decline. The S&P 500 has risen 3.3% during the same timeframe.
The renowned provider of POCs has a market capitalization of $189.26 million. The company projects 16.3% earnings growth for 2026 and anticipates continued business improvements going forward. Inogen’s P/S ratio of 0.5 compared with the industry’s 3.05 makes its valuation attractive.
Image Source: Zacks Investment Research
Let’s delve deeper.
Factors Driving INGN’s Prospects
Demand for POCs & Market Shift: Inogen is benefiting from a structural shift in the long-term oxygen therapy (LTOT) market toward portable oxygen concentrators (POCs). Its lightweight, battery-powered systems, such as the Inogen One and Inogen Rove, enable greater mobility and convenience compared to traditional stationary concentrators and oxygen tanks. Adoption is accelerating, with about 59% of new LTOT patients starting on POCs and unit volumes growing over 20% year over year in 2025.
Diversified Product Portfolio & Expanding TAM: Inogen’s expanding product lineup positions it well for future growth.The company has expanded beyond POCs into airway clearance (Simeox), stationary oxygen (Voxi 5) and sleep therapy (Aurora CPAP masks). These additions increase its TAM from $400 million to over $3 billion. Early traction is encouraging, with Simeox generating over $6 million in 2025 revenues and Voxi 5 showing strong initial uptake. The upcoming CPAP mask launch targets a $2.2 billion market, with significant cross-selling potential.
International Expansion: International markets emerged as a clear bright spot, with fourth-quarter 2025 revenues growing 15% year over year to $32.5 million. Growth was driven by stronger demand, deeper relationships with home medical equipment (HME) providers and success in securing key tenders. Management emphasized that global COPD markets remain underpenetrated, with long-term oxygen therapy still underutilized in many regions. This creates a multi-year runway for expansion.
INGN: Key Risks to Watch
U.S. Revenue Pressure & Channel Mix Shift: Fourth-quarter 2025 U.S. sales declined 5.1% year over year, reflecting both delayed customer orders and a broader shift toward B2B channels. While B2B growth supports volume expansion, it creates headwinds for higher-margin direct-to-consumer (DTC) and rental segments. This evolving channel mix is expected to continue pressuring near-term revenue visibility and margins.
Macroeconomic Concerns: Inogen faces macroeconomic risks that could pressure demand and operations. Factors such as inflation, interest rate changes, geopolitical instability and weaker consumer spending may lead customers, distributors and healthcare providers to delay or reduce purchases of respiratory equipment. Global supply chain constraints around raw materials and semiconductor components used in portable oxygen concentrators can raise procurement costs and create sourcing challenges. These pressures may increase the cost of sales, compress margins and limit the company’s ability to meet demand efficiently.
Inogen has been witnessing a negative estimate revision trend for 2026. In the past 60 days, the Zacks Consensus Estimate for its loss per share has expanded by 21 cents to 72 cents.
The Zacks Consensus Estimate for 2026 revenues is pegged at $369.2 million, suggesting a 5.9% improvement from the year-ago reported number.
Shares of GMED have gained 7.4% in the year-to-date period. Estimates for the company’s 2026 earnings per share (EPS) have increased by 1 cent to $4.46 in the past 30 days. GMED’s earnings surpassed estimates in three of the trailing four quarters and missed one, the average surprise being 18.8%. In the last reported quarter, it delivered an earnings surprise of 20.8%.
PAHC shares climbed 44.8% in the year-to-date period. Estimates for the company’s 2026 EPS have remained constant at $3.03 in the past 30 days. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 20.1%. In the last reported quarter, it delivered an earnings surprise of 26.1%.
CAH shares lost 0.3% in the year-to-date period. Estimates for the company’s 2026 EPS have increased by 1 cent to $10.32 in the past 30 days. CAH’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 9.3%. In the last reported quarter, it posted an earnings surprise of 10%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
Key Takeaways
Inogen, Inc. (INGN - Free Report) is well-poised for growth in the coming quarters, backed by high prospects in the portable oxygen concentrator (POC) space. The optimism, led by a diversified and expanding product portfolio, strong momentum in international markets and a growing total addressable market, seems justified. However, U.S. revenue pressure from channel shifts and macroeconomic conditions remains a key risk.
This Zacks Rank #3 (Hold) company’s shares have gained 3.6% in the year-to-date period against the industry’s 12.7% decline. The S&P 500 has risen 3.3% during the same timeframe.
The renowned provider of POCs has a market capitalization of $189.26 million. The company projects 16.3% earnings growth for 2026 and anticipates continued business improvements going forward. Inogen’s P/S ratio of 0.5 compared with the industry’s 3.05 makes its valuation attractive.
Image Source: Zacks Investment Research
Let’s delve deeper.
Factors Driving INGN’s Prospects
Demand for POCs & Market Shift: Inogen is benefiting from a structural shift in the long-term oxygen therapy (LTOT) market toward portable oxygen concentrators (POCs). Its lightweight, battery-powered systems, such as the Inogen One and Inogen Rove, enable greater mobility and convenience compared to traditional stationary concentrators and oxygen tanks. Adoption is accelerating, with about 59% of new LTOT patients starting on POCs and unit volumes growing over 20% year over year in 2025.
Diversified Product Portfolio & Expanding TAM: Inogen’s expanding product lineup positions it well for future growth.The company has expanded beyond POCs into airway clearance (Simeox), stationary oxygen (Voxi 5) and sleep therapy (Aurora CPAP masks). These additions increase its TAM from $400 million to over $3 billion. Early traction is encouraging, with Simeox generating over $6 million in 2025 revenues and Voxi 5 showing strong initial uptake. The upcoming CPAP mask launch targets a $2.2 billion market, with significant cross-selling potential.
International Expansion: International markets emerged as a clear bright spot, with fourth-quarter 2025 revenues growing 15% year over year to $32.5 million. Growth was driven by stronger demand, deeper relationships with home medical equipment (HME) providers and success in securing key tenders. Management emphasized that global COPD markets remain underpenetrated, with long-term oxygen therapy still underutilized in many regions. This creates a multi-year runway for expansion.
INGN: Key Risks to Watch
U.S. Revenue Pressure & Channel Mix Shift: Fourth-quarter 2025 U.S. sales declined 5.1% year over year, reflecting both delayed customer orders and a broader shift toward B2B channels. While B2B growth supports volume expansion, it creates headwinds for higher-margin direct-to-consumer (DTC) and rental segments. This evolving channel mix is expected to continue pressuring near-term revenue visibility and margins.
Macroeconomic Concerns: Inogen faces macroeconomic risks that could pressure demand and operations. Factors such as inflation, interest rate changes, geopolitical instability and weaker consumer spending may lead customers, distributors and healthcare providers to delay or reduce purchases of respiratory equipment. Global supply chain constraints around raw materials and semiconductor components used in portable oxygen concentrators can raise procurement costs and create sourcing challenges. These pressures may increase the cost of sales, compress margins and limit the company’s ability to meet demand efficiently.
Inogen, Inc Price
Inogen, Inc price | Inogen, Inc Quote
INGN’s Estimate Trend
Inogen has been witnessing a negative estimate revision trend for 2026. In the past 60 days, the Zacks Consensus Estimate for its loss per share has expanded by 21 cents to 72 cents.
The Zacks Consensus Estimate for 2026 revenues is pegged at $369.2 million, suggesting a 5.9% improvement from the year-ago reported number.
Key Picks
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Phibro Animal Health (PAHC - Free Report) and Cardinal Health (CAH - Free Report) . While GMED sports a Zacks Rank #1 (Strong Buy) at present, PAHC and CAH carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Shares of GMED have gained 7.4% in the year-to-date period. Estimates for the company’s 2026 earnings per share (EPS) have increased by 1 cent to $4.46 in the past 30 days. GMED’s earnings surpassed estimates in three of the trailing four quarters and missed one, the average surprise being 18.8%. In the last reported quarter, it delivered an earnings surprise of 20.8%.
PAHC shares climbed 44.8% in the year-to-date period. Estimates for the company’s 2026 EPS have remained constant at $3.03 in the past 30 days. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 20.1%. In the last reported quarter, it delivered an earnings surprise of 26.1%.
CAH shares lost 0.3% in the year-to-date period. Estimates for the company’s 2026 EPS have increased by 1 cent to $10.32 in the past 30 days. CAH’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 9.3%. In the last reported quarter, it posted an earnings surprise of 10%.